Key result
Orlistat at concentrations of 25 and 100 μM significantly reduced the expression of OCT4 and SOX2, and at 100 μM significantly reduced KLF4 and Nanog expression in the SW40 colorectal cancer cell line.
Why the study?
The study aimed to evaluate the effect of the anti-obesity drug orlistat on the expression of OCT4, Nanog, SOX2, and KLF4 genes in the colorectal cancer SW40 cell line.
Does orlistat reduce the expression of OCT4, Nanog, SOX2, and KLF4 genes in colorectal cancer SW40 cells?
Does orlistat reduce the expression of OCT4, Nanog, SOX2, and KLF4 genes in colorectal cancer SW40 cells?
Orlistat significantly reduces the expression of stemness-related genes (OCT4, Nanog, SOX2, KLF4) in colorectal cancer cells in vitro.
May suppress stemness in colorectal cancer cells in vitro; leaves open clinical translation pending in vivo studies.
BACKGROUND AND OBJECTIVE: Orlistat drug is one of the most criticalanti-obesity drugs that widely used around the world. The aim of this study was evaluation the effect of orlistat on the expression of OCT4, Nanog, SOX2, and KLF4 genes in the colorectal cancer SW40 cell line. MATERIALS AND METHODS: SW40 cell line was cultured in DMEM medium contained orlistat for 24h, and cell viability was assessed by MTT assay. The fold changes of expression of OCT4, NANOG, KLF4, and SOX2 at mRNA level against β-actin were determined by real-timePCR. Two-sample t-test and one-way ANOVA were used to compare the mean of expression of different genes in different groups and different concentrations; a significant level of 0.05 was considered in all tests. RESULTS: Our results showed a significant difference in cell viability, when different doses of Orlistat were used for 24 hour. concentrations of 25 and 100 μM reduce significantly the expression of OCT4 (p <0.05) and SOX2 (p <0.05) in the treated group in comparison to control (p <0.05). Also, the mRNA expression of KLF4 and Nanog was reduced significantly after treatment of SW40 cell lines was performed with 100 μM doses of Orlistat (p <0.05). CONCLUSION: It appears that after further studies in animal and human phases, orlistat can be used for the treatment of Colorectal Cancer. .
No takes yet. Share an insight, caveat, or question.
Karimabad et al. (2021) studied Colorectal cancer (SW40 cell line). Orlistat vs. Control (no orlistat) was evaluated on Expression of OCT4, Nanog, SOX2, and KLF4 genes (p=<0.05). Orlistat at concentrations of 25 and 100 μM significantly reduced the expression of OCT4 and SOX2, and at 100 μM significantly reduced KLF4 and Nanog expression in the SW40 colorectal cancer cell line.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: